Tests liposomal irinotecan, TAS102 and bevacizumab in metastatic colorectal cancer
Tests liposomal irinotecan, TAS102 and bevacizumab in adults with treatment-resistant metastatic colorectal cancer.
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Registry title
- Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 13 Oct 2023
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- Liposomal irinotecan
- TAS102
- Bevacizumab
- Record updated
- 15 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer that has spread or cannot be removed by surgery, and that has already been treated before.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Colorectal adenocarcinoma, confirmed by tissue or cell tests, that has spread (metastatic) or cannot be removed by surgery. The cancer must be mismatch repair proficient. ECOG performance status must be 0 or 1.
- Earlier treatment
- Must have had treatment with 5-fluorouracil, oxaliplatin and irinotecan regimens. If RAS wild-type: prior cetuximab or panitumumab. If RAS wild-type and HER2 positive: prior HER2 targeted therapy. Must not have had TAS102 before.
- Biomarker or test result
- Mismatch repair proficient cancer. Cancers with BRAF V600 mutations, mismatch repair deficiency or high microsatellite instability cannot join.
Main reasons for not taking part
- Cancer with a BRAF V600 mutation
- Mismatch repair deficient or microsatellite instability high cancer
- Prior treatment with TAS102
- Uncontrolled other illness that would prevent finishing the planned therapy
- Use of strong CYP3A4 inducers or inhibitors within 2 weeks before starting
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients must be ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance must be 0 or 1
- Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable
- The cancer must be mismatch repair proficient
- Patients must have had prior treatment with 5-fluorouracil, oxaliplatin, irinotecan containing regimens. If RAS wild-type must have received prior anti-EGFR therapy with either cetuximab or panitumumab. If RAS wild-type and HER2 positive then must have had a prior HER2 targeted therapy
Who cannot take part
- Uncontrolled concurrent medical illness that would not allow for the completion of the planned therapy
- Patients must stop the use of strong inducers/inhibitors of CYP3A4 at least 2 weeks before initiating therapy
- Patients must not have received prior TAS102
- Patients whose cancers possess BRAF V600 mutations are excluded
- Patients must not have mismatch repair deficient or microsatellite instability high cancers
This trial is currently available in United States.
- University of Wisconsin Carbone Cancer CenterMadison, United StatesContact: Cancer ConnectTaking people
About the trial
What the trial wants to find out
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
The group in the trial
- Participants with Metastatic or Unresectable Colorectal CancerTreatment being tested
Male and females aged 18 years and older with histologically confirmed metastatic or unresectable (not amenable to curative therapy) colorectal cancer.
Treatment: Liposomal irinotecan, TAS102, and Bevacizumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
- Plain-language title
- Tests liposomal irinotecan, TAS102 and bevacizumab in metastatic colorectal cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 September 2026